Revisiting the role of cladribine in acute myeloid leukemia: An improvement on past accomplishments or more old news?
Authors:
- 25 October 2014
- journal article
- review article
- Published by Wiley in American Journal of Hematology
- Vol. 90 (1) , 62-72
Abstract
Originally studied in lymphoid diseases, cladribine (CdA) is an adenosine deaminase resistant analog of adenosine that was later discovered to induce myeloid cell apoptosis. The activity of CdA in myeloid malignancies was first reported in relapsed/refractory (RR) pediatric acute myeloid leukemia (AML) with complete response (CR) rates of up to 47%. Consequently, several studies have confirmed the efficacy of single agent CdA or CdA combination regimens in AML. Established CR rates for combination regimens in RR adults are approximately 50%, while CR rates for newly diagnosed (ND) adults are approximately 70% and show similar toxicity profiles to previously used regimens. Despite these promising data, many centers have yet to adopt CdA combination regimens for these difficult to treat populations. We review the pharmacology, pharmacokinetics, clinical data, and safety of CdA monotherapy and combination regimens for the management of pediatric and adult ND and RR‐AML. Am. J. Hematol. 90:62–72, 2015.Keywords
Funding Information
- National Cancer Center (CA016156)
- National Cancer Institute (P30CA016156)
This publication has 67 references indexed in Scilit:
- Beyond hairy cell: the activity of cladribine in other hematologic malignanciesBlood, 2010
- Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemiaCancer, 2009
- Anthracycline Dose Intensification in Acute Myeloid LeukemiaNew England Journal of Medicine, 2009
- High-Dose Daunorubicin in Older Patients with Acute Myeloid LeukemiaNew England Journal of Medicine, 2009
- Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trialLeukemia, 2009
- Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G‐CSF (CLAG‐M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia GroupEuropean Journal of Haematology, 2007
- 2-Chlorodeoxyadenosine inhibits activity of adenosine deaminase and S-adenosylhomocysteine hydrolase in patients with chronic lymphocytic leukaemiaEuropean Journal of Cancer, 1997
- The Comparison of 2-Chlorodeoxyadenosine (2-Cd A) in Combination with Interferon α (IFN α) or Interferon γ (IFN γ) on Granulocyte-Macrophage Progenitor Cells (CFU-GM) and Clonogenic Blasts in (CFU-L) In Vitro CulturesLeukemia & Lymphoma, 1996
- Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissuesEuropean Journal of Cancer, 1995
- Lasting Remissions in Hairy-Cell Leukemia Induced by a Single Infusion of 2-ChlorodeoxyadenosineNew England Journal of Medicine, 1990